Evonik in the news

Evonik's stock increased due to higher Q2 2026 earnings and receiving a significant sustainability award for packaging technology.

Evonik's TEGO Res 1100, a co-binder for printing inks, won the 2026 German Packaging Award for significantly improving the deinking process in packaging recycling.

Constantia Flexibles and Evonik received the German Packaging Award 2026 for their TEGO Res 1100 deinking technology, which enhances the recyclability of flexible plastic packaging.

Constantia Flexibles and Evonik secured the German Packaging Award 2026 for their deinking technology, TEGO Res 1100, which improves ink removal from flexible plastic packaging to enhance recycling.

Evonik Industries stock is trading near its yearly highs, driven by strong performance, restructuring progress, and a shift towards higher-margin specialty chemicals and lipid products, resulting in improved revenue and profitability.

Evonik has appointed Claus Rettig as interim CEO and Deputy Chairman of the Executive Board while Christian Kullmann recovers from surgery.

Evonik is investing over $108 million to triple its lipid-based pharmaceutical manufacturing capacity in Vancouver, with production expected by 2029.

Evonik is investing over 150 million CAD in a new GMP drug product manufacturing facility in Vancouver to expand its lipid-based drug delivery capabilities and support pharmaceutical and biotech customers.

Evonik is investing C$150 million in a new Vancouver plant to significantly expand its manufacturing of advanced lipid-based pharmaceutical products, including vaccines and therapeutics.

Evonik is investing $108 million in a new GMP drug product manufacturing facility in Vancouver, Canada, for lipid-based drug delivery, tripling its current capacity.

Evonik's new acrylate-based co-binder, TEGO Res 1100, significantly improves the recyclability of plastic packaging by enabling rapid, low-temperature de-inking of solvent-borne inks, reducing energy use and greenhouse gas emissions.

Claus Rettig takes interim leadership at Evonik, assuming CEO responsibilities temporarily while Christian Kullmann recovers from surgery.

Evonik is cutting 3,200 jobs and exiting the polyester business due to high energy costs and global economic weakness.

Evonik is cutting 3,200 jobs and exiting its loss-making polyester business to improve operational efficiency.

Evonik stock price surged 5% after a Deutsche Bank analyst predicted the company will significantly beat its second-quarter profit targets.

Evonik is divesting its Hanau pharmaceutical production assets to ProChem Group to focus on advanced drug delivery and biosolutions.

Evonik is cutting 3,200 jobs and shutting down its unprofitable global polyester business to address structural disadvantages and improve efficiency.

German specialty chemicals maker Evonik is cutting 3,200 jobs and selling its polyester business to reduce costs and boost efficiency.

Stock prices fell after the company announced 3,200 job cuts and the shutdown of its underperforming polyester division due to a difficult economic climate.

European chemical stocks including Evonik are declining as geopolitical tensions ease and the company announces job cuts and a business divestment.